Strategic partnerships There is strong momentum in clinical adoption of ARC-EX with recent facility acquisitions and expansion into Europe via STEPS Rehabilitation and Touchstone Rehabilitation, presenting opportunities to partner with providers for clinic deployment, training, and service integration.

At home adoption ARC-EX is FDA-cleared for clinic and at-home use, highlighting a market need for home-based neurostimulation therapies and potential expansion through payer conversations and patient access programs.

Diversified pipeline Investigation of ARC-IM for blood pressure instability and ARC-BCI for thought-driven movement indicates multiple entry points across SCI symptoms, enabling cross-sell to clinics seeking comprehensive neurostimulation solutions.

Funding and scale With substantial funding and a revenue trajectory including first-quarter device sales across dozens of clinics, there is capacity to support rapid expansion, field teams, and targeted sales to high-need geographies.

Market visibility Recognition such as TIME Best Inventions and Fast Company World Changing Ideas, coupled with CE Marked ARC-EX, strengthens credibility for outreach to key rehabilitation centers, hospitals, and payer networks.